Sirnaomics’ STP707 Shows Promising Results in Phase I Pancreatic Cancer Trial
Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company, has announced the successful completion of a Phase...
Shandong Junxiu Biotechnology Partners with Swiss Firm Geistlich to Boost Regenerative Medicine
Shandong Junxiu Biotechnology Co., Ltd, a Chinese manufacturer of implantable regenerative medicine devices, has entered...
Genmab and AbbVie’s Epcoritamab Earns FDA Accelerated Approval for Follicular Lymphoma
Genmab A/S (NASDAQ: GMAB), a Danish biotechnology company, and its co-development partner AbbVie (NYSE: ABBV),...
AbbVie Bolsters Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition
AbbVie (NYSE: ABBV), a major U.S. pharmaceutical company, has announced the acquisition of Celsius Therapeutics...
Novo Nordisk Plans Cautious Wegovy Launch in China to Preserve Global Supply
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading healthcare company, has reportedly planned a cautious...
Novo Nordisk Moves to Acquire 2seventy bio’s Hemophilia A Program and Gene-Editing Technology
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading Danish biopharmaceutical company, is transitioning from a...
Hybio Pharmaceutical Gets FDA Nod for Tirzepatide Raw Materials in DMF Filing
Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese pharmaceutical company, has announced that it has...
Abbisko Therapeutics Presents Positive Phase II Results for HCC Treatment at ESMO-GI
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotech company, has announced the presentation of...
China’s Kingfriend Biochemical Acquires U.S.-Listed Adalimumab Biosimilar Yusimry for USD 40 Million
Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced the...
Shanghai Kehua Bioengineering’s Subsidiary to Acquire Remaining Stake in Technogenetics S.P.A.
Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022), a Chinese bioengineering company, has announced that its...
Dizal Pharmaceutical’s Golidocitinib Breaks Record with Rapid Market Launch in China
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a biopharmaceutical company based in China, has seen its...
GenScript Biotech Receives Over USD 410 Million in Milestone Payments for CAR-T Therapy from Janssen Biotech
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...
Jianke.com, China’s Leading Chronic Disease Management Platform, Files for Hong Kong IPO
Jianke.com, a China-based smart healthcare service platform, has filed for an initial public offering (IPO)...
TowardPi Medical Secures RMB 200 Million in Series D Financing Led by Matrix Partners
TowardPi (Beijing) Medical Technology Ltd, a Chinese medical technology company, has reportedly secured RMB 200...
Amoy Diagnostics Partners with Servier to Develop Companion Diagnostic Reagent for IDH Mutations in China
China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has entered into a partnership with French...
CDE Seeks Public Input on Latest Batch of Generic Chemical Reference Preparations
The Center for Drug Evaluation (CDE), a key component of China’s National Medical Products Administration...
HighTide Therapeutics Completes Enrollment for Two Phase III Trials of T2DM Drug Candidate HTD1801
HighTide Therapeutics Inc., (HKG: 2511), a biopharmaceutical company based in China, has announced the completion...
Shanghai Junshi Biosciences’ Toripalimab Gains NMPA Nod for First-Line TNBC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that it has received...
Harbour BioMed Resubmits Biological License Application for Batoclimab in China
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
Shanghai’s Phrontline Biopharma Secures Over RMB 100 Million in Pre-Series A Funding for ADC Development
Shanghai-based antibody drug conjugate (ADC) specialist Phrontline Biopharma has reportedly secured over RMB 100 million...